CiVentiChem Appoints Glenn Killingworth to Drive Business Development into New R&D and Pilot Plant Investments in North Carolina

FOR IMMEDIATE RELEASE
Cary, North Carolina, United States of America (Free-Press-Release.com) September 27, 2010 -- CiVentiChem has appointed Glenn Killingworth as Director of Business Development as part of the company's overall growth strategy in support of recent investments at both their US headquarters in North Carolina and their pilot and production facility in Hyderabad, India,. Glenn’s vast experience in the field will benefit the launch of their new assets in Hyderabad, India and cGMP kilo-lab synthesis capabilities in Cary, North Carolina.

Glenn brings over 20 years experience of sales, marketing, collaborative ventures and business development in both Europe and the US, along with a strong scientific background in the field of pharmaceutical and chemistry research and development.

He joins CiVentiChem from his most recent position as Director of Key Accounts at WiXi AppTec where he was responsible for the development of European-centric global pharmaceutical companies. Previously, Glenn held a post on the Operational Board at Peakdale Molecular. During his role at Almac Sciences, in Northern Ireland, he worked with both European and US-based companies. Previously he was Business Development Manager at Fisher Scientific UK, where he successfully introduced Fisher Scientifics' custom synthesis business in the US marketplace.

“Glenn has built a proven track record of commercial success through sales development, strategic marketing and novel collaborative ventures,” said Bhaskar Venepalli, President of CiVentiChem. “We are delighted to have Glenn on board at a very critical juncture of our growth plans and our drive to expand our market share with the investments we recently made in North Carolina as well as in Hyderabad, India” said Venepalli.

“I am delighted to join CiVentiChem’s management team at an exciting time in the company's expansion,” added Glenn. “The multinational business model of US Headquarters and R&D and development capabilities in the US and India offers a compelling solution to pharmaceutical clients. I admire the enthusiasm and teamwork, enabling innovative approaches to solving complex chemistry problems,” said Killingworth.

About CiVentiChem: Headquartered in the regional research and development stronghold of North Carolina’s Research Triangle, CiVentiChem, through its core competence of complex organic chemistry, has forged a successful business providing pharmaceutical, biotechnology and agrochemical companies with contract research, custom synthesis, process development and contract manufacturing services. The company was founded by Bhaskar Venepalli and Duke University scientist Srinivas Chittineni in 1994 and now employs 65 people.

contract manufacture     custom synthesis     medicinal chemistry     organic chemistry     Pharmaceutical R D     process development